Spots Global Cancer Trial Database for A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Official Title: First-in-Human Dose Study of IOA-244 Alone and in Combination With Pemetrexed/Cisplatin in Patients With Advanced or Metastatic Cancers
Study ID: NCT04328844
Study Description
Brief Summary: The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Humanitas Research Hospital, Rozzano, Milan, Italy
Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, , Italy
Beatson West of Scotland Cancer Centre, Glasgow, , United Kingdom
Contact Details
Name: Michael Lahn
Affiliation: iOnctura
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
